Purpose

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.

Condition

Eligibility

Eligible Ages
Over 40 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0, M0. - Microscopic multifocal disease is only allowed when the entire span of identified disease measures 3.0 cm or less. - Negative surgical margins ( ≥ 0.2 cm) after final surgery. - Subjects with infiltrating lobular histologies or high nuclear grade DCIS will be required to have breast MRI scanning as part of the initial staging to verify localized disease. - Subjects with DCIS will be included in the study only if they had an MRI prior to lumpectomy. - Findings on MRI scanning revealing relevant suspicion of disease outside of planned lumpectomy volume should be further evaluated by ultrasound and, if necessary biopsy, to exclude multicentric/multifocal disease. - Subjects with malignant calcifications on mammography will be required to have repeat mammography after surgery to ensure removal of all malignant calcifications. - Willing to complete additional screening requirements and meet eligibility criteria as defined in protocol Sec. 4.4. - Successful placement of fiducial markers for IGRT requiring nonmigrating fiducials. - PTV to ipsilateral breast ratio (IBR) ≤ 25 %. - Radiotherapy anticipated to begin within 10 weeks of lumpectomy or re-excision of margins.

Exclusion Criteria

  • Pregnancy or breast-feeding. - Have collagen-vascular disease. - Inadequate surgical margins ( < 0.2 cm) after final surgery. - Subjects with persistent malignant/suspicious micro-calcifications. - Gross multifocal disease and microscopic disease greater than 3.0 cm.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
IMRT
Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
  • Radiation: accelerated partial breast irradiation - IMRT planning
    38.5 Gy, 10 fractions over 5 days
    Other names:
    • APBI
    • EBRT
Active Comparator
3D-CRT
Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
  • Radiation: accelerated partial breast irradiation - 3D-conformal planning
    38.5 Gy, 10 fractions over 5 days
    Other names:
    • APBI
    • EBRT

Recruiting Locations

Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado 80012

Rocky Mountain Cancer Centers - Boulder
Boulder, Colorado 80303

Rocky Mountain Cancer Centers - Lakewood
Lakewood, Colorado 80228

Rocky Mountain Cancer Centers - Littleton
Littleton, Colorado 80120

Rocky Mountain Cancer Centers - Thornton
Thornton, Colorado 80260

More Details

NCT ID
NCT01185132
Status
Recruiting
Sponsor
Rocky Mountain Cancer Centers

Study Contact

Rachel Lei, BS
303-418-7607
rachel.lei@usoncology.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.